FDA approves AZ's COVID drug for immunocompromised

Thursday, 09. December 2021 05:16

The United States Food and Drug Administration (FDA) has authorized AstraZeneca’s injectable COVID-19 antibody drug for use in people who have increased vulnerability to the virus.

The FDA emergency approval paves the way for the drug, titled Evusheld, to be distributed across the country for adults and adolescents with compromised immune systems or those who have had allergic reactions to the shot.

"Today's action authorizes the use of the combination of two monoclonal antibodies to reduce the risk of developing COVID-19 in these individuals," said Patrizia Cavazzoni, director of the FDA's Center for Drug Evaluation and Research.

Related Links: AstraZeneca plc
Baha Breaking News (BBN) / NL